Prescription Drug Prices

Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and

Even though the pharmaceutical industry had been highly profitable and contributed about 40% OF Ciba-Geigy’s revenues in profit, there were some trends, which were worrying. The government had attempted to reduce a cost of healthcare thus; pressure to lower costs was mounting on industrialized countries. There were restrictions to introduce new products, and price control became stricter while limiting the freedom of doctors to prescribe medications. Patent controls were becoming reduced, and the pharmaceutical industry was becoming increasingly criticized. These trends later made the industry to

"Although prices are often justified by the high cost of drug development, there is no evidence of an association between research and development costs and prices. Rather, prescription drugs are priced in the United States primarily on the basis of what the market will bear." (Ramsey, 2016)

If the pricing is too high, the volume of patients to be served may decrease, thereby, effecting profitability and availability to all those who need it. Exhibit 4 of this case provides data from experts in the various countries on volume and low, medium, and high pricing. The data clearly indicates that the US market is not price sensitive and volume does not change regardless of pricing. The skimming strategy and pricing in the US at the highest end ($2200/dose) would maximize profit and provide a perceived prestige of the new product. Medi-Cult has a 2-3year timeframe, where it is the pioneer of this product and there are no competitors in the market. If after 2-3 years, competitors enter the market in the US, Medi-Cult has the option of reducing pricing without harm as the profits have possibly covered research and development expense by that time. Since insurance reimbursement varies across the nation and is low, this is not a key factor in making this decision. In addition, the US may have higher shipping costs, expense in complying with FDA regulations and the difference in currency. However, Denmark, France and the UK have varying price sensitivities, free treatments and insurance reimbursement seem superior in these countries. They have more uniform currency with EU. There are 3 scenarios to consider: Pricing such that there is maximum profit in each country, pricing such that there is maximum profit in the region with less cumbersome pricing strategy and third global pricing which may reduce profitability in general. Choosing regional pricing of $1167/dosage does not change the volume for the UK or Denmark and may only slightly change volume for France. This pricing may keep competitors from entering the market quickly as perhaps, it is not as attractive. $1167/dose is the maximizing profit level for the UK and the least impact on

Other opponents charge that the high prices of drugs aren’t examples of price gouging at all, but necessary increases for drug makers to recoup costs of research and development. Yet a Health Affairs study shows otherwise: enough money is made by US drug companies that they could cover research and development and still save “US patients, businesses, and taxpayers approximately $40 billion” per year, if they operated like the rest of the world.

The prices of prescription drugs in the United States are by far the highest in the world. [1] On average, Europeans pay 40% less than Americans for the same medications. [2] Consumers have been resorting to several ways, sometimes putting themselves in harm’s way, to alleviate the burden of high prescription drug costs. Some buy their medications online or cross the borders to neighboring countries so they would be able to afford buying their needed medications. Others have resorted to the illegal act of selling their unused medications in online forums just to recover part of their expenses. Many factors contribute to the increased drug prices in the United States including research and

The rise in drug prices is causing the public to ask why this is so and why there isn’t anything being done, or what the reason could be for sky high prices. Some of the reasons include pharmaceutical companies setting their drug prices

The rise in costs of prescription medicines affects all sectors of the health care industry, including private insurers, public programs, and patients. Spending on prescription drugs continues to be an important health care concern, particularly in light of rising pharmaceutical costs, the aging population, and increased use of costly specialty drugs. In recent history, increases in prescription drug costs have outpaced other categories of health care spending, rising rapidly throughout the latter half of the 1990s and early 2000s. (Kaiseredu.org, 2012).

In the business of drug production over the years, there have been astronomical gains in the technology of pharmaceutical drugs. More and more drugs are being made for diseases and viruses each day, and there are many more drugs still undergoing research and testing. These "miracle" drugs are expensive, however, and many Americans cannot afford these prices.

Prescription drug prices are on the rise in the United States. Currently, the United States does not implement a price control on prescription drugs. Every day the supply and demand for prescription drugs fluctuates. Pharmaceutical companies produce drugs that are necessary for survival. Therefore, it is necessary for research and development to continue in the United States. Those suffering the effects of exorbitant prices must do so until a generic form of a prescription drug is produced. Once approved by the FDA, new drugs will make their appearance on the market and patients will no longer suffer financially. Until then, it is necessary for pharmaceutical companies to price their drugs based on the idea of supply and demand. This produces the profit used to fund research. Price controls discourage innovation. If a price control were set in place, of course the price of prescription drugs would decrease. However, the development of new drugs decreases with it. Today’s generation would benefit from lower prices, while future generations would suffer from the loss of drug innovation.

Background: Americans pay the highest prices for prescription drugs in the world. Drug costs increased 12.6 percent last year, more than double the rise in overall medical costs. A new Kaiser Health poll shows that most Americans think prescription drug costs in this country are unreasonable, and that drug companies put profits before people.1 Take the example of albendazole which is broad spectrum anti-parasitic drug. In late 2010, the listed average wholesale price for albendazole was $5.92 per typical daily dose in the United States and less than $1 per typical daily dose overseas. By 2013, the listed typical daily dose price for USA market had increased to $119.58. Medicaid data show that spending on albendazole increased from less than $100,000 per year in 2008, when the average cost was $36.10 per prescription, to more than $7.5 million in 2013, when the average cost was $241.30 per prescription2. Albendazole is a very basic medicine but if we take the case of oncology medicines we are going to realize that oncology drugs have become synonymous with extremely high cost. The average cancer drug price for approximately 1 year of therapy was less than 10,000 per year in 2010 and had increased to $30,000 to $50,000 by 2005. In 2012, 12 of the 13 new drugs approved for cancer indications were priced above $100,000 per year of therapy. With typical out-of-pocket expenses of 20% to 30%, the financial burden would be $20,000 to 30,000 a year, nearly half of the average annual

Drug prices are set by pharmaceutical companies to cover research and development costs. While R&D costs clearly need to be covered, markets in developed countries already pay for most R&D of new products. Because of this, it makes moral and economical sense to establish a two-tiered pricing system; for R&D costs to be paid for by developed countries, allowing significantly reduced prices to be charged in developing countries.

Recently, there has been a debate about the high prescription drug prices in the United States. Accounting for 9.7% of the national health expenditure, $329.2 billion was spent on prescription medications ($931 per person) in 2011 (Linton, 2014). So what exactly is the average American getting with their $931? Well, because there is an extraordinary amount of time, effort, and energy that goes into creating, manufacturing, and distributing a new drug, it’s no wonder the prices are so high. But what other costs are folded into the prices of your prescribed medications? This review looks beyond just the research and development costs needed to take a new drug from idea to shelf by examining several journals and other credible, secondary sources, to shed some light on how much pharmaceutical companies are spending to develop, advertise, and sell their drugs.

Drug pricing is a complex phenomena. Different countries have different methodologies of pricing such as Germany has reference based pring. Canada has system of fixing pricing of patented drugs. India fix the prices of prescription drugs on the basis of cost of the drug.

Hypothesis: The manipulation of patents and market pricing have allowed pharmaceutical companies to raise the prices on drugs necessary for individuals in the US compared. With no competition, the companies are able to exploit the patent system to maximizing profits with no regard to the consumers economic welfare. The price of pharmaceuticals are constantly higher than the rest of the world and the people of America are paying that price.